News - Theravance

Filter

Current filters:

Theravance

Popular Filters

1 to 25 of 40 results

US FDA approves GSK/Theravance’s Anoro Ellipta for COPD

US FDA approves GSK/Theravance’s Anoro Ellipta for COPD

19-12-2013

The US Food and Drug Administration late yesterday approved Anoro Ellipta (umeclidinium and vilanterol…

Anoro ElliptaGlaxoSmithKlineNorth AmericaPharmaceuticalRegulationRespiratory and PulmonaryTheravance

Relvar Ellipta approved for asthma and COPD in Europe

Relvar Ellipta approved for asthma and COPD in Europe

19-11-2013

The European Commission has granted marketing authorization for Relvar Ellipta (fluticasone furoate/vilanterol…

EuropeGlaxoSmithKlinePharmaceuticalRegulationRelvar ElliptaRespiratory and PulmonaryTheravance

Theravance and GSK launch Breo Ellipta in USA

Theravance and GSK launch Breo Ellipta in USA

30-10-2013

GlaxoSmithKline and US partner Theravance today announced that Breo Ellipta for COPD is available to…

Breo ElliptaFinancialGlaxoSmithKlineMarkets & MarketingNorth AmericaPharmaceuticalRespiratory and PulmonaryTheravance

Positive CHMP recommendation for Relvar Ellipta

20-09-2013

UK pharma giant GlaxoSmithKline (LSE: GSK) and US partner Theravance (Nasdaq: THRX) announced that the…

EuropeGlaxoSmithKlinePharmaceuticalRegulationRespiratory and PulmonaryTheravance

FDA advisory panel gives thumbs up for Anoro Ellipta approval

11-09-2013

There was a bit of good news for UK pharma giant GlaxoSmithKline yesterday (LSE: GSK) and partner USA-based…

Anoro ElliptaGlaxoSmithKlineNorth AmericaPharmaceuticalRegulationRespiratory and PulmonaryTheravance

GSK's Anoro Ellipta shows efficacy in COPD, say FDA briefing papers

09-09-2013

UK drug major GlaxoSmithKline's (LSE: GSK) Anoro Ellipta (vilanterol/umeclidinium) to treat chronic obstructive…

Anoro ElliptaBreo ElliptaGlaxoSmithKlineNorth AmericaPharmaceuticalRegulationRespiratory and PulmonaryTheravance

Theravance reintroduces Vibativ in USA

14-08-2013

US drug developer Theravance (Nasdaq: THRX) says it has commenced shipments of Vibativ (telavancin) into…

Antibiotics and Infectious diseasesAstellas PharmaMarkets & MarketingNorth AmericaPharmaceuticalProductionTheravanceVibativ

GlaxoSmithKline and Theravance withdraw Japan NDA for Relvar Ellipta in COPD

12-07-2013

UK pharma giant GlaxoSmithKline (LSE: GSK) and US partner Theravance (Nasdaq: THRX) revealed on Friday…

Asia-PacificBiotechnologyGlaxoSmithKlinePharmaceuticalRegulationRelvar ElliptaRespiratory and PulmonaryTheravance

Hikma licenses Vibativ from Theravance for MENA region

02-07-2013

Jordon-headquartered Hikma Pharmaceuticals (LSE: HIK) says it has signed an exclusive commercialization…

Antibiotics and Infectious diseasesHikma PharmaceuticalsLicensingPharmaceuticalRest of the WorldTheravanceVibativ

GlaxoSmithKline files for umeclidinium monotherapy approval in Europe

29-04-2013

UK pharma giant GlaxoSmithKline (LSE: GSK) has submitted a regulatory application in the European Union…

BiotechnologyEuropeGlaxoSmithKlinePharmaceuticalRegulationRespiratory and PulmonaryTheravanceumeclidinium

GlaxoSmithKline and Theravance file for Japanese approval of Anoro Ellipta

22-04-2013

UK pharma giant GlaxoSmithKline (LSE: GSK) and US partner Theravance (Nasdaq: THRX) today April 22) announced…

Anoro ElliptaAsia-PacificGlaxoSmithKlinePharmaceuticalRegulationRespiratory and PulmonaryTheravance

FDA advisory panel backs approval of COPD drug Breo Ellipta

18-04-2013

Having earlier this week been presented with ambivalent briefing papers, the US Food and Drug Administration's…

Breo ElliptaGlaxoSmithKlineNorth AmericaPharmaceuticalRegulationRespiratory and PulmonaryTheravance

GlaxoSmithKline and Theravance file for EU approval of UMEC/VI for COPD

10-01-2013

UK pharma giant GlaxoSmithKline (LSE: GSK) and US partner Theravance (Nasdaq: THRX) yesterday submitted…

AnoroBiotechnologyEuropeGlaxoSmithKlinePharmaceuticalRegulationRespiratory and PulmonaryTheravanceUMEC/VIumeclidiniumvilanterol

Mixed FDA panel vote for Theravance's Vibativ for nosocomial pneumonia

03-12-2012

US drug developer Theravance (Nasdaq: THRX) saw its shares rise more than 5% $22.48 by close of trading…

Antibiotics and Infectious diseasesPharmaceuticalRegulationTheravanceVibativ

Theravance and Merck & Co enter cardiovascular disease accord

17-10-2012

Drug developer Theravance (Nasdaq: THRX) has signed a collaboration agreement with pharma giant Merck…

Cardio-vascularLicensingMerck & CoPharmaceuticalTheravance

1 to 25 of 40 results

Back to top